Bleeding-Related Episodes (BRE) in Patients With Immune Thrombocytopenia (ITP) Receiving Eltrombopag (EPAG) or Romiplostim (ROMI): Real World Evidence From 26 US Institutions

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.834
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Highly Fluctuating Thrombocytopenia Developing in a Patient With Immune Thrombocytopenia (ITP) While Administering Romiplostim

Internal Medicine
Internal MedicineMedicine
2012English

Thrombopoietin Level Predicts Response to Treatment With Eltrombopag and Romiplostim in Immune Thrombocytopenia

American Journal of Hematology
Hematology
2018English

Self-Administration of Romiplostim in Patients With Chronic Immune Thrombocytopenia

Community Oncology
2013English

Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia

British Journal of Haematology
Hematology
2018English

Eltrombopag in Preparation for Surgery in Patients With Severe Myh9 ‐Related Thrombocytopenia

American Journal of Hematology
Hematology
2019English

The Efficacy and Safety of Romiplostim in Adult Patients With Chronic Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2012English

Determining the Cost of a Bleeding-Related Episode in Primary Adult Chronic Immune Thrombocytopenia (ITP) in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2016English

Eltrombopag-Based Combination Treatment for Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy